阿司匹林对子痫前期高危女性生物标志物谱的影响
这项前瞻性纵向巢式病例对照研究纳入2007名单胎妊娠女性,比较子痫前期高危服用阿司匹林者与低危未治疗者孕期平均动脉压、子宫动脉搏动指数、胎盘生长因子及可溶性fms样酪氨酸激酶-1的变化;高危中发生子痫前期者上述生物标志物轨迹更差。
要点
- 低危组全孕期平均动脉压、子宫动脉搏动指数及可溶性fms样酪氨酸激酶-1的多重中位数对数值较低,胎盘生长因子较高(P<.001)。
- 高危女性中发生子痫前期者平均动脉压、子宫动脉搏动指数及可溶性fms样酪氨酸激酶-1较高,胎盘生长因子较低(P<.001)。
- 高危女性即使服用低剂量阿司匹林,发生子痫前期者仍呈现从早孕期开始的高平均动脉压等生物标志物轨迹。
核心结论
- 服用低剂量阿司匹林的高危女性中,发生子痫前期者从早孕期起平均动脉压持续较高且孕期不变,自中孕期起子宫动脉搏动指数较高、胎盘生长因子较低,晚孕期可溶性fms样酪氨酸激酶-1较高。
- 这些发现强调上述生物标志物在阿司匹林给药后高危女性子痫前期进一步风险分层中的作用。
研究设计与样本
- 前瞻性纵向巢式病例对照研究,纳入2007名单胎妊娠女性,参与中国香港特别行政区威尔士亲王医院2020年1月至2023年5月的早孕期子痫前期筛查与预防项目。
- 早产型子痫前期风险采用胎儿医学基金会三联试验(母体因素、平均动脉压、子宫动脉搏动指数、胎盘生长因子)评估。
- 高危女性(校正风险≥1:100)根据母体体重每日服用阿司匹林100或160 mg,从16周前开始至36周或分娩或36周前发生子痫前期。
- 低危女性按母亲年龄、体重和扫描日期匹配,随访时间为12至15+6周、20至24+6周和30至37+6周。
主要发现
- 研究包括403例无子痫前期的低危女性、1471例无子痫前期的高危女性和133例发生子痫前期的高危女性。
- 低危组全孕期平均动脉压、子宫动脉搏动指数和可溶性fms样酪氨酸激酶-1的多重中位数对数值的估计边际均值显著低于高危组,胎盘生长因子的多重中位数对数值的估计边际均值显著高于高危组(P<.001)。
- 高危女性中发生子痫前期者全孕期平均动脉压多重中位数对数值的估计边际均值为0.06378 vs 0.02985(P<.001),子宫动脉搏动指数为0.08651 vs 0.02226(P<.001),可溶性fms样酪氨酸激酶-1为0.13204 vs 0.01234(P<.001),胎盘生长因子为-0.33504 vs -0.16388(P<.001),均与未发生子痫前期的高危女性比较。
- 单个孕周分析中,与未发生子痫前期的高危女性相比,发生子痫前期者在三个孕期平均动脉压多重中位数对数值均较高,中孕期和晚孕期子宫动脉搏动指数较高、胎盘生长因子较低,晚孕期可溶性fms样酪氨酸激酶-1较高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is limited evidence in the literature regarding the temporal changes of preeclampsia-related biomarkers during pregnancy in high-risk women who develop preeclampsia despite the administration of aspirin prophylaxis. OBJECTIVE: This study aimed to compare the temporal changes in mean arterial pressure, uterine artery pulsatility index, placental growth factor, and soluble fms-like tyrosine kinase-1 across gestation in women identified as having high risk for preterm preeclampsia receiving aspirin prophylaxis and low-risk women without aspirin treatment. STUDY DESIGN: This was a prospective longitudinal nested case-control study of 2007 women with singleton pregnancies who participated in the first-trimester screen-and-prevent program for preeclampsia at the Prince of Wales Hospital, Hong Kong Special Administrative Region, China, between January 2020 and May 2023. The risk of developing preterm preeclampsia was determined using the Fetal Medicine Foundation triple test (maternal factors, mean arterial pressure, uterine artery pulsatility index, and placental growth factor). High-risk women (adjusted risk ≥1:100) were administered a daily dose of aspirin at either 100 or 160 mg according to maternal weight, starting before 16 weeks until 36 weeks or until delivery or the onset of preeclampsia before 36 weeks. Low-risk women were matched according to maternal age, weight, and the date of the scan. The participants were followed up at 12 to 15+6, 20 to 24+6, and 30 to 37+6 weeks to measure mean arterial pressure, uterine artery pulsatility index, placental growth factor, and soluble fms-like tyrosine kinase-1 at each visit. The level of biomarker was expressed as multiple of the median. Log10 transformation was applied to fit the data to a Gaussian distribution before statistical analysis. A linear mixed-effects analysis was performed to compare the longitudinal changes of these biomarkers across gestation between the study groups. RESULTS: Our study involved 403 low-risk women without preeclampsia, 1471 high-risk women without preeclampsia, and 133 high-risk women who developed preeclampsia. The low-risk group had significantly lower estimated marginal mean log10 mean arterial pressure multiple of the median, log10 uterine artery pulsatility index multiple of the median, and log10 soluble fms-like tyrosine kinase-1 multiple of the median, and higher estimated marginal mean log10 placental growth factor multiple of the median across gestation compared with the high-risk groups (P<.001). Among high-risk women, those who developed preeclampsia exhibited a significantly higher estimated marginal mean log10 mean arterial pressure multiple of the median (0.06378 vs 0.02985; P<.001), log10 uterine artery pulsatility index multiple of the median (0.08651 vs 0.02226; P<.001), and log10 soluble fms-like tyrosine kinase-1 multiple of the median (0.13204 vs 0.01234; P<.001), and lower estimated marginal mean log10 placental growth factor multiple of the median (-0.33504 vs -0.16388; P<.001) across gestation compared with those without preeclampsia. In the individual gestational time point analysis, compared with high-risk women without preeclampsia, those who developed preeclampsia exhibited higher log10 mean arterial pressure multiple of the median in all 3 trimesters, higher log10 uterine artery pulsatility index multiple of the median and lower log10 placental growth factor multiple of the median in the second and third trimesters, and higher log10 soluble fms-like tyrosine kinase-1 multiple of the median in the third trimester. CONCLUSION: This study demonstrated that high-risk women who developed preeclampsia consistently exhibited high mean arterial pressure levels from the first trimester that remained unchanged during pregnancy, high uterine artery pulsatility index levels and low placental growth factor levels starting from the second trimester, and high soluble fms-like tyrosine kinase-1 levels in the third trimester compared with those who did not develop preeclampsia despite the administration of low-dose aspirin. These findings underscore the role of these biomarkers in further risk stratification for the development of preeclampsia among high-risk women following aspirin administration.
引用
- Nguyen-Hoang L, Sahota DS, Tai AST, et al. Effect of aspirin on biomarker profile in women at high risk for preeclampsia. Am J Obstet Gynecol. 2024. PMID: 39547345. doi:10.1016/j.ajog.2024.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。